^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SGN-CD228A

    i
    Other names: SGN-CD228A, SGN CD228A
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, CD228-targeted antibody-drug conjugate
    Related drugs:
    over1year
    SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. (PubMed, Mol Cancer Ther)
    Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is being investigated in an ongoing Phase I clinical trial (NCT04042480) in patients with advanced solid tumors.
    Preclinical • Journal
    |
    MELTF (Melanotransferrin)
    |
    MELTF expression • MFI2 expression
    |
    SGN-CD228A
    almost2years
    A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=88, Terminated, Seagen Inc. | Trial completion date: Sep 2024 --> Mar 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Mar 2023; Study closed due to portfolio prioritization
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative • EGFR wild-type
    |
    SGN-CD228A
    almost2years
    A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=88, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=210 --> 88
    Enrollment closed • Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative • EGFR wild-type
    |
    SGN-CD228A
    almost3years
    A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Seagen Inc. | Trial completion date: Jan 2023 --> Sep 2024 | Trial primary completion date: Jan 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative • EGFR wild-type
    |
    SGN-CD228A
    over4years
    [VIRTUAL] SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. (ASCO 2020)
    Enrollment is ongoing in the US and planned in Europe. Research Funding: Seattle Genetics Inc.
    Clinical • P1 data
    |
    MELTF (Melanotransferrin)
    |
    SGN-CD228A